These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23802423)

  • 21. Modified high amylose starch for immobilization of uricase for therapeutic application.
    Mulhbacher J; McGeeney K; Ispas-Szabo P; Lenaerts V; Mateescu MA
    Biotechnol Appl Biochem; 2002 Dec; 36(3):163-70. PubMed ID: 12452799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PEG-uricase in the management of treatment-resistant gout and hyperuricemia.
    Sherman MR; Saifer MG; Perez-Ruiz F
    Adv Drug Deliv Rev; 2008 Jan; 60(1):59-68. PubMed ID: 17826865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The case for uricase in gout.
    Pay S; Terkeltaub AR
    Curr Rheumatol Rep; 2003 Jun; 5(3):213-4. PubMed ID: 12744813
    [No Abstract]   [Full Text] [Related]  

  • 24. Prediction of Therapeutic Effect of Rasburicase on Hyperuricemia Associated with Chemotherapy Based on Theoretical Model.
    Kimura K; Kanehira N; Takayanagi R; Minohara H; Homma M; Yamada Y
    Biol Pharm Bull; 2016; 39(5):705-11. PubMed ID: 27150142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegloticase (krystexxa) for treatment of refractory gout.
    Med Lett Drugs Ther; 2011 Feb; 53(1357):9-10. PubMed ID: 21304442
    [No Abstract]   [Full Text] [Related]  

  • 26. Alternative treatment for chronic gout could relieve pain for thousands. The recently approved intravenous drug, pegloticase, may work when other treatments don't.
    Duke Med Health News; 2013 Jan; 19(1):3. PubMed ID: 23762971
    [No Abstract]   [Full Text] [Related]  

  • 27. Gout therapeutics: new drugs for an old disease.
    Burns CM; Wortmann RL
    Lancet; 2011 Jan; 377(9760):165-77. PubMed ID: 20719377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase.
    Kelly SJ; Delnomdedieu M; Oliverio MI; Williams LD; Saifer MGP; Sherman MR; Coffman TM; Johnson GA; Hershfield MS
    J Am Soc Nephrol; 2001 May; 12(5):1001-1009. PubMed ID: 11316859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immobilization of uricase within polystyrene using polymaleimidostyrene as a stabilizer and its application to uric acid sensor.
    Wang X; Hagiwara T; Uchiyama S
    Anal Chim Acta; 2007 Mar; 587(1):41-6. PubMed ID: 17386751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Xanthine oxidoreductase and its inhibitors: relevance for gout.
    Day RO; Kamel B; Kannangara DR; Williams KM; Graham GG
    Clin Sci (Lond); 2016 Dec; 130(23):2167-2180. PubMed ID: 27798228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
    Sundy JS; Becker MA; Baraf HS; Barkhuizen A; Moreland LW; Huang W; Waltrip RW; Maroli AN; Horowitz Z;
    Arthritis Rheum; 2008 Sep; 58(9):2882-91. PubMed ID: 18759308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout.
    Tan PK; Farrar JE; Gaucher EA; Miner JN
    Mol Biol Evol; 2016 Sep; 33(9):2193-200. PubMed ID: 27352852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Data on changes in blood and urinary uric acid induced by a urate oxidase].
    Villiaumey J; Larget-Piet B; Rotterdam M
    Rev Rhum Mal Osteoartic; 1972 Feb; 39(2):138-40. PubMed ID: 4563394
    [No Abstract]   [Full Text] [Related]  

  • 35. Self-Cascade Uricase/Catalase Mimics Alleviate Acute Gout.
    Lin A; Sun Z; Xu X; Zhao S; Li J; Sun H; Wang Q; Jiang Q; Wei H; Shi D
    Nano Lett; 2022 Jan; 22(1):508-516. PubMed ID: 34968071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immobilized-enzyme nylon-tube reactor for routine determination of uric acid in serum.
    Sundaram PV; Igloi MP; Wassermann R; Hinsch W
    Clin Chem; 1978 Oct; 24(10):1813-7. PubMed ID: 699291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An amperomertic uric acid biosensor based on immobilization of uricase onto polyaniline-multiwalled carbon nanotube composite film.
    Bhambi M; Sumana G; Malhotra BD; Pundir CS
    Artif Cells Blood Substit Immobil Biotechnol; 2010 Aug; 38(4):178-85. PubMed ID: 20367113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancement of skin permeation of bufalin by limonene via reservoir type transdermal patch: formulation design and biopharmaceutical evaluation.
    Yang Z; Teng Y; Wang H; Hou H
    Int J Pharm; 2013 Apr; 447(1-2):231-40. PubMed ID: 23467076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
    Bomalaski JS; Holtsberg FW; Ensor CM; Clark MA
    J Rheumatol; 2002 Sep; 29(9):1942-9. PubMed ID: 12233890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Modalities of purine excretion during enzyme treatment of gout and other hyperuricemic conditions with urate oxidase].
    Royer R; Vindel J; Lamarche M; Kissel P
    Presse Med (1893); 1968 Dec; 76(49):2325-7. PubMed ID: 5737250
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.